COVID-19 drug

CSIR-IICT will be the knowledge partner for the clinical trial study and 101 Therapeutics, a CRO will manufacture the drug

GlobalData expects Spikevax vaccine market share to decline from 30 per cent in 2022 to just 16 per cent by the end of 2028

The agreement is valid between 14th December and 30th November, 2023, China Meheco said in a filing to the Shanghai stock exchange

Merck added that Sinopharm is the only legally authorised distributor of Merck's COVID-19 anti-viral molnupiravir in China

Pfizer signed a deal in August for Chinese drugmaker Zhejiang Huahai to produce Paxlovid in mainland China solely for patients…

Their findings, based on research with fruit flies and mouse heart cells, were published in 'Communications Biology,' a 'Nature'…

In March, Fujifilm had cut short enrolment in a phase-III trial, saying the emergence of the Omicron variant made it tough to…

A tripartite Memorandum of Agreement was signed among BARC, ACTREC-TMC and IDRS to develop Chlorophyllin against COVID-19 disease…

The annual sales of Dolo 650 have been Rs 360 crore, about eight per cent of the company sales

The generic drug belongs to an old, widely-used class of antidepressants called Selective Serotonin Reuptake Inhibitors (SSRIs)